About the Master

Zhang Jing is Vice President of Green Valley Research Institute and Director of the Department of Biology.

About the e-Class

GV-971, being the world’s first AD drug that targets the gut-brain axis, reduces peripheral and central inflammation by reconditioning the gut microbiota and inhibiting the abnormal increase of gut microbiota-derived metabolites. On November 2, 2019, China’s National Medical Products Administration approved GV-971 as a new drug for the treatment of "mild-to-moderate AD and improving cognitive function", after granting fast-track review for the drug.